Abstract:Objective:To report a case of lung adenocarcinoma of stage Ⅳ with epidermal growth factor receptor (EGFR) mutation treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance,and to review the related literatures.Methods:A female patient without smoking history was diagnosed with lung adenocarcinoma (stage cT3N2M1 Ⅳ) with metastatic lesions in liver and bones by chest CT,lung puncture biopsy,and whole-body PET-CT.EGFR gene test reported mutation (19 del).Through treatment of overall survival,pemetrexed disodium for injection plus carboplatin injection,gemcitabine hydrochloride for injection plus cisplatin injection,paclitaxel for injection (albumin bound) single and with bevacizumab;the overall survival (OS) was assessed as 32 months.And the period of Erlotinib HCL Tablets showed 10 months of progressive-free survival (PFS).However,due to the metastatic lesions that suppressed biliary system in liver,hyperbilirubinemia emerged (total bilirubin 304 μmol · L-1,direct bilirubin 193 μmol · L-1).Bevacizumab was adopted and the syndrome relieved (total bilirubin 70 μmol · L-1,direct bilirubin 35 μmol · L-1),yielding three months of PFS.But the bilirubin level upgraded with total bilirubin of 908 μmol · L-1.The patient died because of hyperbilirubinemia.Results:10-month PFS occupied 1/3 of OS was acquired in the patients with EGFR-mutated lung adenocarcinoma (stage Ⅳ) after treated with Erlotinib HCL Tablets.Chemotherapy combined with bevacizumab acquired 3 months of PFS after hyperbilirubinemia emerged with drug resistance and multi-lines of chemotherapy.Conclusion:EGFR-TKIs are effective in treatment of lung adenocarcinoma with EGFR mutation;bevacizumab can inhibit the formation of vessels by targeting on VEGF under the circumstance of multiple drug resistance.Therefore,chemotherapy combined with bevacizumab can be used as the fifth-line of therapy in dealing with the hyperbilirubinemia induced by lung adenocarcinoma with liver metastasis.

Erlotinib in a Patient with Vaginal Carcinoma and Pulmonary Metastasis: A Case Report

Female genital tract metastasis of lung adenocarcinoma with EGFR mutations: Report of two cases

Clinical Efficacy of Erlotinib in Patients Previously Treated for Advanced Non‐small Cell Lung Cancer

Small Bowel Perforation Secondary to Metastatic Lung Cancer with Emphasis on the Administration of Erlotinib: a Case Report

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

Hepatic Metastasis is a Poor Predictive Marker for Erlotinib in Lung Adenocarcinoma

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib As 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer

Efficacy and Safety of Erlotinib in the Treatment for Advanced Non-Small Cell Lung Cancer in Chinese Patients

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Conventional Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Quick Regression of Brain Metastases from Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Case Report and Literature Review.

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

Epithelioid trophoblastic tumor with lung metastasis: A case report and literature review

Lung Adenocarcinoma with EGFR Gene Mutation Metastatic to the Uterine Cervix: A Case Report.

[Role of Erlotinib 100 Mg/d in the Treatment of Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy].

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

[Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases.].

Erlotinib in Combination with Chemotherapy for Patients with Advanced Pancreatic Cancer

Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance: A case report and literature review

Predictive Effects of Serum Vegf, Tgf-A and Egfr Mutations in Advanced Non-Small Cell Lung Cancer Treated by Erlotinib